Postby GrouseMan » Sat Feb 25, 2017 12:40 am
This. Is Abbvie's Rova-T antibody drug conjugate drug which they are primarily targeting for Small Cell Lung Cancer, a particularly difficult cancer to treat. About 18% of the people that stayed with the drug and we're able to be evaluated saw tumor regression. Many more saw stable disease. It targets a tumor cell surface protein called DLL3 in the notch pathway, and the conjugated drug is toxic and can kill the cancer. I think this is very new attempt to use this to target CRC.
Regards
GrouseMan.
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017